Targeted therapy and blood-brain barrier

Recent Results Cancer Res. 2007:176:123-33. doi: 10.1007/978-3-540-46091-6_10.

Abstract

Due to defined molecular lesions and signaling pathway disruptions, brain tumors represent good candidates for targeted therapy. However, in brain tumors the blood-brain barrier may prevent the transfer of progress in the molecular neurosciences to the development of effective therapeutic strategies. In this article, the most advanced forms of targeted therapy for the treatment of brain tumors and their clinical results are presented.

Publication types

  • Review

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / metabolism
  • Antibodies / administration & dosage
  • Antibodies / metabolism
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols
  • Blood-Brain Barrier / metabolism*
  • Brain Neoplasms / drug therapy*
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Liposomes
  • Oligonucleotides, Antisense / administration & dosage
  • Oligonucleotides, Antisense / metabolism
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / metabolism

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Angiogenesis Inhibitors
  • Antibodies
  • Antineoplastic Agents
  • Liposomes
  • Oligonucleotides, Antisense
  • Protein Kinase Inhibitors
  • ErbB Receptors